Biweekly carboplatin plus nab-paclitaxel with concurrent radiotherapy followed by durvalumab consolidation for unresectable locally advanced non-small cell lung cancer: a real-world retrospective cohort study
Yasuhito Nunomura, Hisashi Tanaka, Shintaro Oyama, Toko Miura, Haruka Odagiri, Yuri Kobori, Kei Chubachi, Mina Ishidoya, Hiroaki Sakamoto, Tomonori Makiguchi, Dai Miura, Takeshi Morimoto, Yukihiro Hasegawa, Kageaki Taima, Sadatomo Tasaka · 2026
Read Biweekly carboplatin plus nab-paclitaxel with concurrent radiotherapy followed by durvalumab consolidation for unresectable locally advanced non-small cell lung cancer: a real-world retrospective cohort study by Yasuhito Nunomura, Hisashi Tanaka, Shintaro Oyama, Toko Miura, Haruka Odagiri, Yuri Kobori, Kei Chubachi, Mina Ishidoya, Hiroaki Sakamoto, Tomonori Makiguchi, Dai Miura, Takeshi Morimoto, Yukihiro Hasegawa, Kageaki Taima, Sadatomo Tasaka (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13263800.txt.
Description
Yasuhito Nunomura and colleagues examined in 2026 a gentler chemotherapy rhythm paired with radiation, then immune therapy, for advanced lung cancer that surgery cannot remove. Two Japanese centers treated 75 patients between 2018 and 2022 with carboplatin and nab-paclitaxel given every two weeks alongside radiation. Most then moved on to durvalumab as consolidation.
From the start of immune therapy, median time without progression reached sixteen months and median survival about thirty-eight months. Eighty-eight percent of patients made the transition to durvalumab, including over three quarters of those aged seventy-five and older. The older group finished consolidation less often yet matched the younger group on survival. Lung inflammation was common but usually manageable, with severe cases near one in eight. The authors present the schedule as a workable option even for older patients.
Catalog record
| CREATOR | Yasuhito Nunomura, Hisashi Tanaka, Shintaro Oyama, Toko Miura, Haruka Odagiri, Yuri Kobori, Kei Chubachi, Mina Ishidoya, Hiroaki Sakamoto, Tomonori Makiguchi, Dai Miura, Takeshi Morimoto, Yukihiro Hasegawa, Kageaki Taima, Sadatomo Tasaka |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 33 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |